NE001

NE001 is an exosome-based therapeutic candidate developed by Shanghai Saierxin Biomedical Technology (NovaBioTx). It is currently in the discovery and process development stage, specifically targeting autoimmune skin diseases and related conditions. The therapy utilizes exosomes—extracellular vesicles that transport proteins, lipids, and nucleic acids—to modulate immune responses and promote tissue repair in the skin. The mention of "INCI" (International Nomenclature Cosmetic Ingredient) in the company's pipeline suggests that the development process may also involve standards applicable to cosmetic or dermatological ingredients.